Genmab's Phase 2 Trial Shows Tisotumab Vedotin Achieves 32.5% Objective Response Rate In Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
Genmab's Phase 2 trial results show that Tisotumab Vedotin achieved a 32.5% objective response rate in patients with head and neck cancer.
June 03, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's Phase 2 trial results for Tisotumab Vedotin show a 32.5% objective response rate in head and neck cancer, indicating potential efficacy and boosting investor confidence.
The positive Phase 2 trial results for Tisotumab Vedotin suggest potential efficacy in treating head and neck cancer, which is likely to boost investor confidence and positively impact Genmab's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100